KIYATEC utilizes the patient's own living tumor cells to create functional 3D models to test a battery of cancer therapies.
KIYATEC has raised $18.0M in total funding. The most recent round was Series C. The last funding was announced in May 2023.
KIYATEC's investors include LabCorp, Bruker, Seae Ventures, VentureSouth, Brain Tumor Investment Fund.
KIYATEC is headquartered in Greenville, United States.
KIYATEC utilizes the patient's own living tumor cells to create functional 3D models to test a battery of cancer therapies.
KIYATEC is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"KIYATEC — Funding & Investors." VCBacked, May 18, 2023, https://www.vcbacked.co/company/kiyatec. Accessed September 15, 2026.
VCBacked. (2023). KIYATEC — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/kiyatec
{{cite web |title=KIYATEC — Funding & Investors |url=https://www.vcbacked.co/company/kiyatec |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated